Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix

被引：44

作者：

Donaldson, S. B. ^{[1
,2
]}

Buckley, D. L. ^{[2
,3
]}

O'Connor, J. P. ^{[2
,4
]}

Davidson, S. E. ^{[5
]}

Carrington, B. M. ^{[4
]}

Jones, A. P. ^{[1
]}

West, C. M. L. ^{[6
]}

机构：

[1] The Christie, NW Med Phys, Manchester M20 4BX, Lancs, England

[2] Univ Manchester, Manchester M13 9PT, Lancs, England

[3] Univ Leeds, Div Med Phys, Leeds LS2 9JT, W Yorkshire, England

[4] The Christie, Dept Radiol, Manchester M20 4BX, Lancs, England

[5] The Christie, Dept Clin Oncol, Manchester M20 4BX, Lancs, England

[6] Univ Manchester, Sch Canc Imaging Sci, Manchester M20 4BX, Lancs, England

来源：

BRITISH JOURNAL OF CANCER | 2010年 / 102卷 / 01期

关键词：

enhancing fraction; dynamic contrast-enhanced MRI; cervix cancer; radiotherapy; imaging biomarkers; CANCER; CHEMOTHERAPY; RADIOTHERAPY; PARAMETERS;

D O I：

10.1038/sj.bjc.6605415

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: There is a need for simple imaging parameters capable of predicting therapeutic outcome. METHODS: This retrospective study analysed 50 patients with locally advanced carcinoma of the cervix who underwent dynamic contrast-enhanced MRI before receiving potentially curative radiotherapy. The proportion of enhancing pixels (E(F)) in the whole-tumour volume post-contrast agent injection was calculated and assessed in relation to disease-free survival (DFS). RESULTS: Tumours with high EF had a significantly poorer probability of DFS than those with low E(F) (P = 0.011). INTERPRETATION: EF is a simple imaging biomarker that should be studied further in a multi-centre setting. British Journal of Cancer (2010) 102, 23-26. doi:10.1038/sj.bjc.6605415 www.bjcancer.com Published online 17 November 2009 (C) 2010 Cancer Research UK

引用

页码：23 / 26

页数：4

共 15 条

[1] Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix [J].

Cooper, RA ;

Carrington, BM ;

Loncasters, JA ;

Todd, SM ;

Davidson, SE ;

Logue, JP ;

Luthra, AD ;

Jones, AP ;

Stratford, I ;

Hunter, RD ;

West, CML .

RADIOTHERAPY AND ONCOLOGY, 2000, 57 (01) :53-59

[2] Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis [J].

Green, JA ;

Kirwan, JM ;

Tierney, JF ;

Symonds, P ;

Fresco, L ;

Collingwood, M ;

Williams, CJ .

LANCET, 2001, 358 (9284) :781-786

[3]

Hawighorst H, 1998, CLIN CANCER RES, V4, P2305

[4]

Hawighorst H, 1999, MAGN RESON MATER PHY, V8, P55

[5] PHARMACOKINETIC MAPPING OF THE BREAST - A NEW METHOD FOR DYNAMIC MR MAMMOGRAPHY [J].

HOFFMANN, U ;

BRIX, G ;

KNOPP, MV ;

HESS, T ;

LORENZ, WJ .

MAGNETIC RESONANCE IN MEDICINE, 1995, 33 (04) :506-514

[6] Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume [J].

Jayson, GC ;

Parker, GJM ;

Mullamitha, S ;

Valle, JW ;

Saunders, M ;

Broughton, L ;

Lawrance, J ;

Carrington, B ;

Roberts, C ;

Issa, B ;

Buckley, DL ;

Cheung, S ;

Davies, K ;

Watson, Y ;

Zinkewich-Péotti, K ;

Rolfe, L ;

Jackson, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :973-981

[7] Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix [J].

Loncaster, JA ;

Carrington, BM ;

Sykes, JR ;

Jones, AP ;

Todd, SM ;

Cooper, R ;

Buckley, DL ;

Davidson, SE ;

Logue, JP ;

Hunter, RD ;

West, CML .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (03) :759-767

[8] Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: A new noninvasive predictive assay [J].

Mayr, NA ;

Yuh, WTC ;

Magnotta, VA ;

Ehrhardt, JC ;

Wheeler, JA ;

Sorosky, JI ;

Davis, CS ;

Wen, BC ;

Martin, DD ;

Pelsang, RE ;

Buller, RE ;

Oberley, LW ;

Mellenberg, DE ;

Hussey, DH .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (03) :623-633

[9] Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study [J].

Monk, Bradley J. ;

Sill, Michael W. ;

Burger, Robert A. ;

Gray, Heidi J. ;

Buekers, Thomas E. ;

Roman, Lynda D. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1069-1074

[10] Phase I evaluation of a fully human anti-αv integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors [J].

Mullamitha, Saifee A. ;

Ton, Nhuan C. ;

Parker, Geoff J. M. ;

Jackson, Alan ;

Julyan, Peter J. ;

Roberts, Caleb ;

Buonaccorsi, Gio A. ;

Watson, Yvonne ;

Davies, Karen ;

Cheung, Sue ;

Hope, Lynn ;

Valle, Juan W. ;

Radford, John A. ;

Lawrance, Jeremy ;

Saunders, Mark P. ;

Munteanu, Mihaela C. ;

Nakada, Marian T. ;

Nemeth, Jeffrey A. ;

Davis, Hugh M. ;

Jiao, Qun ;

Prabhakar, Uma ;

Lang, Zhihui ;

Corringham, Robert E. ;

Beckman, Robert A. ;

Jayson, Gordon C. .

CLINICAL CANCER RESEARCH, 2007, 13 (07) :2128-2135

← 1 2 →